EVQLV has taken a step ahead in the AI-evolving world to accelerate its business and redefine the healthcare industry's potential values, best aligning with the tech world. The EVQL has introduced Abtique, a first and best the worth online marketplace. At this online marketplace, the scientists can get AI-designed antibody sequences in just one call, quickly.
The Abtique concur with the HyperBind2 launch. HyperBind2 is the AI system built for antibody design, which has been qualified in the majority of labs and described in a new research book.
The Antibodies involve a bulk of world-class popular medicines for asthma, arthritis, cancer and etc. According to the Towards Healthcare study analysis, the antibody market was at its peak, earning around $246 billion in 2024 and might accelerate to $685 billion by 2034. Where researchers, drug developers and scientists are looking for affordable and quick ways to establish drugs there AI is driving transformation and positive change and development prominently throughout the life sciences spectrum.
Though qualifying and building these technologies needs ample years of work, special expertise and prominent costs. As the question arises with this new launch, ‘Why can’t every researcher working on the remarkable science access AI-designed molecules?’ For this, Abtique is the best fit. The CTO of EVQLV, Brett Averso, said, “With the help of Abtique, a scientist can get a lab-ready antibody sequence quickly with no need for any AI expertise, as it is supported by independent lab validation.”
EVQLV’s technology has successfully proven its excellence in over 48 projects throughout the diagnostics companies, huge pharmaceutical companies, well-known academic labs and biopharma. The existing partners have engineered antibodies focusing on MERS, Parkinson’s, cancer, Alzheimer’s and etc.
Director of the Institute of Research and Innovation Parc Tauli in Barcelona, Professor Salvador Ventura, said, “By working with EVQLV, our antibody development has come into fruition. I’ve been engaging in protein design for a long 20 years, and this best exemplifies the antibody-to-target design throughout my career. Their technology has changed the perspective in flipping a challenging approach into a successful result.”
The CEO and co-founder of EVQLV, Andrew Satz, said, “With the promising results we’ve received from independent labs, we’re now thrilled to make proven AI-powered antibody design accessible to all researchers. Now we can confidently work on our goal and mission as well”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
